Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Metastatic Small Intestinal Adenocarcinoma: early-phase trial registry

1 of 3 indexed Metastatic Small Intestinal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Metastatic Small Intestinal Adenocarcinoma: 3 US clinical trials tracked, 1 recruiting.

Metastatic Small Intestinal Adenocarcinoma is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Academic and Community Cancer Research United, running 1 of these trials.

Enrollment posture brief

Registry condition metastatic-small-intestinal-adenocarcinoma

OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Metastatic Small Intesti (th…33%
Open-enrollment share among volume-matched conditions near Metastatic Small Intestinal Adenocarcinoma

Metastatic Small Intestinal Adenocarcinoma lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Small Intestinal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Small Intestinal Adenocarcinoma is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 23

Phase Distribution

PhaseTrial count
Phase 2 3

Named interventions

Most-linked intervention names on Metastatic Small Intestinal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Neomycin Drug
1 trials
Fecal Microbiota Transplantation Capsule Drug
1 trials
Leucovorin Calcium Drug
1 trials
Metronidazole Drug
1 trials
Irinotecan Hydrochloride Drug
1 trials
Fecal Microbiota Transplantation Procedure
1 trials
Irinotecan Drug
1 trials
Laboratory Biomarker Analysis Other
1 trials

US sites by state

Facility locations filed on Metastatic Small Intestinal Adenocarcinoma trials. A trial with sites in several states counts in each.

Texas 2 trials
Arizona 2 trials
South Dakota 1 trials
New York 1 trials
Missouri 1 trials
Minnesota 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Small Intestinal Adenocarcinoma page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Small Intestinal Adenocarcinoma condition card totals 3 registered trials; most-linked intervention Neomycin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.